Shares of IndusInd Bank dropped over 5% on Thursday, even after the private lender reported a 72% year-on-year (YoY) surge in net profit to Rs 1,037 crore for the first quarter of the ongoing FY27, with brokerages raising target prices for the stock.

IndusInd Bank shares fell to Rs 1,015.10 apiece on NSE today, after the private lender on Wednesday released its earnings for the April-June quarter of the financial year 2027. Its net interest income (NII) remained flat at Rs 4,685 crore in Q1 FY27, as compared to Rs 4,640 crore in the same quarter of last year.

Net interest margin improved to 3.57% from 3.46% in the corresponding quarter of the previous year. Provisions and contingencies, excluding tax, fell to Rs 1,384 crore from Rs 1,760 crore a year earlier. This supported the rise in bottom-line profit.

IndusInd Bank’s asset quality improved in the June quarter. Gross non-performing assets stood at 3.25% of gross advances as of June 30, 2026, compared with 3.64% a year earlier and 3.43% as of March 2026. Net NPA ratio improved to 0.95%, compared with 1.12% a year earlier and 1% at the end of the March quarter.

Also read | IndusInd Bank Q1 Results: Profit soars 72% YoY to Rs 1,037 crore; NII flat

Nuvama on IndusInd Bank share price

Nuvama Institutional Equities maintained its ‘Buy’ call on the shares of IndusInd Bank but increased its target price to Rs 1,250 apiece. This implies nearly 17% upside potential from the stock’s previous closing price of Rs 1,069.30 apiece on NSE.

The brokerage said IndusInd’s credit growth trajectory has turned sequentially positive while better NII and lower opex led to a strong 37% beat on profit estimate. The private lender’s management expects asset quality to improve further led by falling stress in MFI and hence LLP, which coupled with better credit growth and opex should put the company firmly on path to 1% exit RoA in FY27, it added.
“We believe IIB under new management is on a firm path of a calibrated turnaround beginning FY27 and should deliver a steady uptick in RoA to 0.8–1.5% over FY27–29,” Nuvama said in its note.

Motilal Oswal on IndusInd Bank share price

Motilal Oswal also raised its target price for IndusInd Bank to Rs 1,125 apiece, implying 5% upside potential, while reiterating its ‘Neutral’ rating on the stock. It also raised its earnings estimates by 18-19% in FY27 and FY28, and project the bank’s RoA at 0.7% in FY27 and 1% in FY28.IndusInd Bank reported a healthy quarter, supported by healthy operating performance and one-off income, the domestic brokerage said. It noted that the bank’s business momentum picked up sequentially, led by strong growth in the corporate segment, while retail book growth remains muted.

“Deposit growth was driven by higher retail deposits, taking the retail deposit share to 49.5% of total deposits. The reduction in slippages was broad-based; however, slippages in the VF and MFI segments inched up due to seasonality, leading to a partial miss on our provision estimates for 1Q. The bank expects loan growth to broadly track industry growth in FY27, with potential to outpace the industry in FY28,” Motilal Oswal said.

IndusInd Bank share price

IndusInd Bank shares gained around 6% in one week and 18% in one month. The stock has gained more than 20% in 2026 so far.

In the longer term, IndusInd Bank shares have jumped around 26% in one year, but fell nearly 24% in three years. In the longer term, the bank’s shares have delivered over 8% return in five years. The company has a market capitalisation of nearly Rs 69,490 crore.

Also read | Dividend alert! Last day to buy Bharti Airtel, Hero MotoCorp, among 43 stocks for dividend payout worth Rs 1,127

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Federal regulators on Monday announced the recall of a popular allergy medication over concerns it may have been cross-contaminated with another drug, potentially causing “life-threatening” reactions.

The U.S. Food and Drug Administration (FDA) said certain lots of Cetirizine hydrochloride Tablets, commonly sold over the counter as generic versions of Zyrtec, are affected by the voluntary recall.

The recall was initiated Saturday by Unique Pharmaceutical Laboratories, a division of J.B. Chemicals & Pharmaceuticals Ltd., based in Panoli, Gujarat, India, according to the FDA.

The affected tablets may be contaminated with ranitidine, a medication once widely used to reduce stomach acid production. Ranitidine, sold under the brand name Zantac, was removed from the U.S. market in 2020 after regulators raised concerns over contamination with a probable human carcinogen. A reformulated version of the medication was later approved by regulators in 2025.

FDA SAYS TAYLOR FARMS CYCLOSPORA LETTUCE TEST WAS A FALSE POSITIVE

The FDA warned that some consumers could experience “serious adverse events,” including anaphylaxis, a rapid and potentially life-threatening allergic reaction.

“For consumers with a hypersensitivity to the ingredients in ranitidine, there is a reasonable probability that ingestion of cetirizine tablets contaminated with ranitidine could result in serious adverse events,” the FDA said. 

Anaphylaxis symptoms may manifest as low blood pressure, difficulty breathing, trouble swallowing, swelling of the throat or face, intense itching, hives and loss of consciousness. 

Unique Pharmaceuticals said it has not received any reports of adverse events associated with the recall.

POPULAR GARLIC POWDER RECALLED NATIONWIDE OVER BACTERIAL CONTAMINATION CONCERNS

The issue was discovered after a pharmacy technician noticed discrepancies while counting tablets during dispensing, according to regulators. Some tablets appeared to have a “red dot,” while others appeared discolored or had multiple red-colored spots. 

The recalled products were reportedly distributed nationwide to wholesalers and retailers.

CLICK HERE TO GET FOX BUSINESS ON THE GO

The affected antihistamine is packaged in a high-density polyethylene (HDPE) bottle containing 100 tablets of 5 mg cetirizine hydrochloride tablets USP under the National Drug Code (NDC) 16571-401-10.

Four manufacturing lots are included in the recall: GY825029, GY825030, GY825031 and GY825032.

All affected lots have an expiration date of October 2028.  

Ticker	Security	Last	Change	Change %
JBCHEPHARM	NO DATA AVAILABLE	–	–	–

Unique Pharmaceuticals has notified its distributor, Rising Pharma Holdings Inc., of the recall. 

Consumers with questions about the recall can contact Rising Pharma Holdings Inc. at 1-844-874-7464 from 8 a.m. to 5 p.m. ET, Monday through Friday or email pv@risingpharma.com. 

Kalshi is asking regulators for permission to let users speculate on the price of gold, silver and platinum with a new kind of derivative contract that never expires.

The prediction-markets provider has filed with the Commodity Futures Trading Commission to start offering perpetual futures contracts linked to the spot price of precious metals.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

The co-founder of Hugging Face, a technology start-up that was hacked after some of OpenAI’s most advanced artificial intelligence (AI) models went rogue, said on Thursday that the incident is “a wake up call” for the industry.

Thomas Wolf told the BBC that “this will be one of the most common types of cyber attacks we see”, but that most companies are not aware that the “game has changed”.

The BBC has contacted OpenAI for comment.

The ChatGPT-maker said on Tuesday that its AI models broke out of a secure test environment during a trial and launched a cyber attack. The firm said the incident was “unprecendented” and that it was conducting an investigation with Hugging Face.

AI agents are able to operate alone to accomplish tasks after human instruction.

Wolf told BBC’s Newsday radio programme that Hugging Face initially had no idea where the attack originated when signs of it surfaced in mid-July but that the company was able to contain the breach.

Hugging Face is one of the world’s largest open-source hubs for sharing AI models and is often used by tech developers and researchers.

Wolf said the breach was “very different” from the usual cyber attacks that Hugging Face often faces and that OpenAI quickly informed the company that its models were behind the hack.

In a “very short time” there were 17,000 attacks on Hugging Face’s network from various IP (Internet Protocol) addresses, said Wolf, who is also the firm’s chief science officer.

The breach is also a warning to other companies that they must strengthen their cybersecurity defences to counter such attacks, Wolf said.

President Donald Trump announced Tuesday that imported generic drugs will remain tariff-free for the next two years before facing steep new import duties, saying the move is designed to encourage pharmaceutical companies to manufacture more medicines in the U.S.

In a Truth Social post, Trump said all generic drugs imported into the U.S. will continue to face a 0% tariff beginning Aug. 1, 2026, for a two-year transition period. After that, the tariff will rise to 100% for one year before increasing to 200%.

“Effective August 1st, 2026, all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for a two-year period of time, after which the TARIFF will be raised to 100% for a one-year period of time, and 200% thereafter,” Trump wrote.

The president said the phased approach is intended to give pharmaceutical companies time to move production to the U.S. before the higher tariffs take effect.

TRUMP ADMINISTRATION HITS CANADA WITH 50% TARIFF OVER ALLEGED TRADE ‘DISCRIMINATION’

“This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them,” Trump wrote.

Trump said the objective of the policy is “to protect the people of the United States.”

The announcement marks the latest effort by the Trump administration to use tariffs as leverage to encourage domestic manufacturing in industries it considers strategically important, including pharmaceuticals. The administration has repeatedly argued that the U.S. has become overly dependent on foreign countries for critical medicines and pharmaceutical ingredients.

Trump said his administration’s existing policy on patented, branded and innovative drugs would remain unchanged.

WHAT ARE THE MAIN STICKING POINTS IN THE TRUMP ADMIN’S TRADE NEGOTIATIONS WITH CANADA, MEXICO?

“The Policy on Patented, Branded, or Innovative Drugs, which has been so successful, will remain as is,” he wrote.

He also pointed to what he described as a surge in domestic investment by drugmakers.

“Pharmaceutical Facilities are being built, at a level never seen before, all over the United States of America,” Trump wrote.

The Association for Accessible Medicines, which represents generic drug manufacturers, said it is seeking additional details on the proposal but supports policies that strengthen domestic manufacturing.

“We need to understand more the specifics of the policy, but the generics industry is committed to pursuing policies that support and stabilize both the industry and the access necessary to ensure patients have reliable options for affordable medicines,” Association for Accessible Medicines President and CEO John Murphy III said in a statement shared with FOX Business.

Murphy said the industry has expanded manufacturing investments in the U.S. over the past two years but argued that structural problems involving purchasing and reimbursement continue to hinder additional growth. He said the group looks forward to working with the administration and Congress on policies to strengthen the domestic generic drug industry.

Generic drugs account for more than 90% of prescriptions filled in the United States, according to the Food and Drug Administration. 

CLICK HERE TO GET FOX BUSINESS ON THE GO

Many also rely on global manufacturing networks and imported active pharmaceutical ingredients, making supply chain resilience a growing focus for policymakers and the pharmaceutical industry.

The announcement gives manufacturers a two-year runway before tariffs begin increasing, allowing companies time to decide whether to build or expand U.S. production facilities or continue importing products while facing substantially higher duties.

Shares of food delivery giant Eternal rose 3% to Rs 291 on the BSE on Thursday after it reported a consolidated profit of Rs 87 crore for the first quarter of FY27, marking an 11% decline from Rs 98 crore posted in the same period last year. The net profit is attributable to the owners of the parent company.

The company’s revenue from operations came in at Rs 20,211 crore, a massive 182% jump from Rs 7,167 crore reported in the corresponding quarter of the previous financial year, Eternal said in a regulatory filing.

On a sequential basis, net profit declined 47% from Rs 174 crore posted in the previous quarter. Revenue from operations, on the other hand, rose 17% from Rs 17,292 crore, according to the company’s exchange filing.

Eternal shares: Buy, sell or hold?

JPMorgan maintained its Overweight rating on Eternal with a target price of Rs 390 (38% upside), calling the quarter strong but broadly in line with expectations, with growth accelerating across quick commerce, food delivery and District.CLSA retained its High Conviction Outperform rating on Eternal with a target price of Rs 506 (79% upside), saying the company’s Q1FY27 results reinforced its view of strong execution. Both quick commerce and food delivery posted faster growth, while profitability improved despite elevated competition.

Blinkit reported faster NOV growth along with greater confidence in profitability and cash generation. Zomato‘s growth accelerated to its fastest pace in six quarters, with limited impact from emerging no-commission platforms. Meanwhile, newer businesses such as District and Bistro continued to expand the ecosystem and drive customer engagement.
Jefferies maintained its Buy rating on Eternal with a target price of Rs 415, saying the first quarter reinforced the importance of quality growth over simply chasing market share. Food delivery growth accelerated alongside better-than-expected profitability, while quick commerce performance remained strong despite falling short of optimistic forecasts. The key takeaway for the brokerage was management’s growing confidence that competitive intensity in quick commerce has become more predictable and that value-led food delivery is unsustainable.
Blinkit does not favour a short-term discounting strategy, and management indicated it is comfortable with the broader market growing faster as a result.
Nomura retained its Buy rating on Eternal with a target price of Rs 350, implying a 24% upside, citing improving quick commerce profitability despite intense competition. Blinkit added 200 stores during the quarter, taking its total store count to 2,443. Management expects margins to continue improving, with competitive intensity having peaked in Q1FY27 and becoming more predictable.

Eternal now expects Blinkit’s steady-state EBITDA margin to reach 6% of NOV, compared with its earlier estimate of 5-6%, driven by efficiencies from larger stores and warehouses, deeper assortments, and better working capital management. The company expects net working capital days to decline from 18 to 12 in the steady state. Nomura forecasts 57-74% year-on-year NOV growth and adjusted EBITDA margins of 0.9-2% in FY27-28F.

Also read: Will Blinkit growth sustain amid competition? 5 things to know from Eternal’s shareholder letter

Motilal Oswal maintained its positive view on Eternal with a target price of Rs 400, implying a 41% upside. Management guided towards the higher end of its long-term margin range, with a reported EBIT margin of around 4% and an adjusted EBITDA margin of around 6%, compared with its earlier guidance range of 5-6%.

This came despite the recent increase in take rates not yet translating into contribution margin gains, which management attributed to minimum wage hikes across several states and the opening of larger stores. With the business model now established and competition becoming more predictable, management expects structurally higher margins going forward.

Motilal Oswal noted that continued elevated competition could affect near-term gains but viewed the guidance upgrade positively. The brokerage said management’s long-term target of 60% NOV growth and an EBITDA target of USD 1 billion by FY29 appear increasingly achievable, with its estimates continuing to factor in this long-term trajectory.

Emkay retained its Buy rating on Eternal and raised its target price by 8.1% to Rs 400 from Rs 370 after the company’s Q1FY27 results exceeded expectations. Emkay expects competitive intensity to remain elevated during the upcoming festive season but said Blinkit has demonstrated its ability to retain market share while maintaining profitability. The brokerage raised its FY27E and FY28E quick commerce NOV estimates by 5.4% and 8%, respectively, citing strong growth momentum. It retained its positive view based on Eternal’s strong execution in quick commerce, steady food delivery momentum, and adequate cash reserves.

Read more:Eternal Q1 Results: Cons PAT skyrockets 268% YoY to Rs 92 crore; revenue zooms 182%

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

This article was written by

SYDNEY — Shares of Commonwealth Bank of Australia climbed Thursday, tracking gains across the country’s major lenders as the broader Australian stock market advanced on the back of strong overnight earnings from U.S. technology giant Alphabet.

CBA shares traded at $173.60 as of Thursday’s session, up $1.91, or 1.11%, on the day. The gain builds on a modest advance in the previous session, when the stock closed at $171.69, and comes as Australia’s benchmark S&P/ASX 200 index climbed 0.72% to near 8,886 points, with financial stocks among the sectors contributing to the day’s broader rally.

A stock near the upper end of its yearly range

Thursday’s gain puts CBA shares within reach of recent highs after a period of relative softness earlier this month. The stock’s 52-week trading range spans from $149.76 to $185.59, meaning current levels sit comfortably in the upper half of that band, even as the stock remains below its yearly peak. CBA’s market capitalization currently stands at approximately $285.08 billion, making it one of the largest companies listed on the Australian Securities Exchange by that measure.

The stock’s recent trajectory has been choppy. According to market reports over the past several weeks, CBA shares have moved between roughly $156 and $164 on a number of individual trading days amid what analysts described as mixed sentiment across the broader banking sector, tied in part to uncertainty around interest rate settings and regulatory scrutiny. Thursday’s advance to $173.60 marks a notable recovery from those levels.

Australia’s largest bank

Founded in 1911 and headquartered in Sydney, Commonwealth Bank of Australia is the country’s largest bank by market value, with operations spanning retail, business and institutional banking across Australia, New Zealand and parts of Asia. The bank’s core offerings include savings and transaction accounts, home loans, credit cards, personal and business lending, insurance products, and equity trading and capital markets services, delivered through its main divisions of Retail Banking Services, Business Banking, Institutional Banking and Markets, and its New Zealand subsidiary, ASB.

Dividend profile

CBA remains one of the ASX’s most closely watched dividend payers, particularly among income-focused investors. The bank most recently paid an interim dividend of $2.35 per share for the six months ended Dec. 31, 2025, with an ex-dividend date of Feb. 18 and a payment date of March 30. Its next dividend, expected at $2.60 per share, carries an ex-dividend date of Aug. 19 and a payment date of Sept. 29, in line with the bank’s typical pattern of announcing dividends alongside its half-year results in February and full-year results in August.

On a trailing basis, CBA’s dividend yield currently sits at roughly 2.9%, with the bank having raised its dividend for five consecutive years and posted average dividend growth of just over 8% annually over the past three years, according to dividend-tracking services.

Why banks moved higher Thursday

CBA’s gain came as part of a broader lift across Australia’s major banking stocks, which factored into Thursday’s advance for the ASX 200 alongside strength in mining and energy names. The rally followed a stronger-than-expected overnight earnings report from Alphabet, which posted a broad beat on both revenue and cloud segment growth, helping to lift risk appetite across global equity markets, including in sectors such as banking that are more closely tied to overall economic sentiment than to the technology earnings themselves.

Separately, fresh domestic economic data released Thursday showed Australia’s unemployment rate holding steady at 4.4%, even as jobs growth for the month came in well above expectations, offering another data point supporting a generally upbeat tone in local markets during Thursday’s session.

Analyst views on valuation

CBA’s share price has drawn ongoing debate among analysts and investment commentators about whether the stock represents good value at current levels. Using a dividend-based valuation approach with an adjusted annual dividend of $4.76 per share, one recent analysis put the bank’s estimated fair value at just over $100 per share, a figure notably below the stock’s current trading price, reflecting a common tension among analysts between CBA’s consistent operating performance and what some view as a premium valuation relative to its earnings and dividend yield.

Morningstar has described CBA’s well-managed net interest margins, sound asset quality and strong balance sheet as continuing to support solid financial results, while cautioning that increased regulatory, political and public scrutiny could, over time, erode the bank’s pricing power and its economic moat. The bank currently trades at a normalized price-to-earnings ratio of roughly 26.3 and a price-to-sales ratio of about 9.7, according to Morningstar data, metrics that place CBA among the more richly valued major banks globally.

CBA is expected to release its full-year results in August, a report that will offer investors a clearer picture of the bank’s overall performance for the 12 months through June, along with confirmation of its previously flagged final dividend of $2.60 per share. Until then, the stock’s near-term direction is likely to remain closely tied to broader market sentiment, movements in the Reserve Bank of Australia’s interest rate settings, and the performance of Australia’s other major lenders, including ANZ, Westpac and National Australia Bank, all of which factor into how investors assess the health of the country’s banking sector as a whole.

For now, Thursday’s 1.11% gain leaves CBA trading well above its 52-week low and within a stone’s throw of its record highs, underscoring the stock’s continued status as one of the most closely watched, and most debated, names on the Australian share market.

More than 300,000 empty lots listed for sale could help reduce America’s housing shortage, according to new research from Zillow.

The real estate company said 300,242 empty lots of five acres or fewer were listed for sale on Zillow in June, accounting for 17.4% of all for-sale listings.

Building one home on each lot would reduce the estimated national housing deficit from 4.7 million homes to about 4.44 million, a decline of 6.3%, Zillow said.

The typical lot for sale is 0.57 acres and has a median price of $79,000. Zillow said many of the parcels may be large enough to support more than one home, making its estimate conservative.

STARTER HOME AFFORDABILITY IS CRAWLING BACK. THESE REGIONS ARE BEST FOR FIRST-TIME HOME BUYERS

“The more than 300,000 lots currently listed for sale represent the lowest-hanging fruit in addressing a housing shortage that’s two decades in the making,” Zillow Senior Economist Kara Ng said.

Ng said loosening zoning rules, streamlining permitting and expanding access to financing could reduce the cost and uncertainty associated with construction.

WHY HOMEBUYERS ARE RACING TO THIS PENNSYLVANIA PORT CITY

Florida had the most empty lots listed for sale, with 42,601, followed by Texas with 40,907, California with 18,508, North Carolina with 14,226 and Georgia with 10,334.

Empty lots made up the largest share of for-sale listings in North Dakota, at 45.9%, followed by South Dakota at 38.7% and Alaska at 34.6%.

Rural markets had the highest concentration of empty lots, accounting for 25.3% of listings, compared with 13.6% in suburban areas and 9% in urban markets.

MORTGAGE RATES JUMP TO HIGHEST LEVEL IN ALMOST A YEAR

Rural lots were also the least expensive on a per-acre basis, with a median of about $75,000 per acre. That compares with more than $181,000 per acre in suburban areas and approximately $500,000 per acre in urban areas.

Zillow said expanding access to manufactured homes could also help address the shortage because they can be built faster and at a lower cost than traditional site-built homes.

CLICK HERE TO GET FOX BUSINESS ON THE GO

The company is participating in a 12-week federal technology initiative with the U.S. Census Bureau’s Opportunity Project focused on increasing access to small-dollar housing loans in rural communities and reducing barriers for buyers interested in purchasing and building on empty lots.